SCHEMBL1848508

SCHEMBL1848508

N#Cc1sc(N)nc1-c1cc(F)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 4/20 0.43
WDR5 P61964 4/20 0.43
USP8 P40818 1/20 0.41
USP7 Q93009 1/20 0.41
USP47 Q96K76 1/20 0.41
AXL P30530 1/20 0.41
GFER P55789 1/20 0.41
CDC7 O00311 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
ADORA1 P30542 5/20 0.39
ADORA2A P29274 4/20 0.39
FBP1 P09467 1/20 0.38
MPL P40238 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852493 0.82 ADORA1 (0.50) MYCWDR5ADORA1ADORA2AMPL
SCHEMBL30309296 0.82 ADORA1 (0.50) MYCWDR5ADORA1ADORA2AMPL
SCHEMBL1852196 0.78 MYC (0.61) MYCWDR5CDC7DBF4ADORA1
SCHEMBL31311375 0.78 MPL (0.47) MYCWDR5CDC7DBF4ADORA1
SCHEMBL1850391 0.78 MPL (0.47) MYCWDR5CDC7DBF4ADORA1
SCHEMBL30309309 0.77 ADORA1 (0.55) MYCWDR5CDC7DBF4ADORA1
SCHEMBL1848775 0.77 ADORA1 (0.55) MYCWDR5CDC7DBF4ADORA1
SCHEMBL1849138 0.75 MYC (0.43) MYCWDR5AXLGFERCDC7
SCHEMBL31311334 0.74 MPL (0.47) MYCWDR5ADORA1ADORA2AMPL
SCHEMBL954791 0.73 KDM4E (0.48) MYCWDR5USP8USP7USP47

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101835766-B As adenosine A1Receptor antagonist compounds PALOBIOFARMA SL 2013-09-25 CN disclosed
US-8410282-B2 Compounds as adenosine A1 receptor antagonists PALOBIOFARMA, S.L. (ES) 2013-04-02 US disclosed
EP-2197860-B1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA SL (ES) 2011-05-25 EP disclosed
US-20100311703-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2010-12-09 US disclosed
EP-2197860-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS Palobiofarma, S.L. (ES) 2010-06-23 EP disclosed
WO-2009044250-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311703-A1 NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 MYC 3683/4885WDR5 4002/4885USP8 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.